Medicilon
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A full-service Chinese CRO providing integrated R&D solutions for small molecules, biologics, and advanced therapies.
OncologyAutoimmune DiseasesInfectious Diseases
Technology Platform
Integrated drug discovery and preclinical development platform encompassing chemistry, biology, DMPK, and safety assessment for small molecules and biologics.
Opportunities
Capitalizing on the global trend of increased R&D outsourcing and the growth of China's biopharma innovation sector.
Risk Factors
Operational risks associated with rapid scaling and intense price competition in the CRO industry.
Competitive Landscape
Competes with large global CROs (e.g., Charles River, WuXi AppTec) and other regional Chinese CROs on service breadth, cost, and efficiency.